MGMT
Denovo Begins Phase III Glioblastoma Trial of Enzastaurin
The firm is evaluating enzastaurin plus chemo and radiation in glioblastoma patients with a biomarker, dubbed de novo genomic marker 1.
Kazia Therapeutics, Kintara Therapeutics Begin Trials in Glioblastoma Platform Study
The companies' treatments, paxalisib and VAL-083, are being studied in the GBM AGILE trial sponsored by the Global Coalition for Adaptive Research.
Bristol Myers Unblinds Trial After Opdivo, Chemoradiation Fail to Extend Survival in Glioblastoma
A data monitoring committee said that BMS's immunotherapy plus standard of care would not improve overall survival in MGMT-methylated brain cancer patients.
Kazia Therapeutics' Paxalisib to be Evaluated in Glioblastoma Study
The multi-cohort brain cancer study will include Kazia's investigational drug in a new arm, which will start enrolling patients in early 2021.
DelMar Close to Completing Phase II Enrollment for Adjuvant VAL-083 in MGMT-Unmethylated GBM
The company, which recently wrapped enrollment for a Phase II trial in China, is continuing to actively enroll patients in the US trial for the drug despite the COVID-19 pandemic.